SEATTLE, Wash., Oct. 20, 2014 /PRNewswire/ -- CTI BioPharma Corp.
(CTI) (NASDAQ and MTA: CTIC) announced today that it will report
its third quarter 2014 financial results on Wednesday, October 29, 2014, after the close of
the U.S. financial markets. Following the announcement, members of
the management team will host a webcast conference call to discuss
the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m.
PDT). Access to the event can be obtained as follows:
Wednesday, October 29
1:30 p.m. PDT/4:30 p.m. EDT/9:30 p.m.
CET
1-888-455-2263 (domestic)
+1 719-325-2376 (international)
To access the live audio webcast or the subsequent archived
recording, visit CTI's website, www.ctibiopharma.com. Webcast and
telephone replays of the conference call will be available at
approximately two hours after completion of the call. Callers can
access the replay by dialing 1-888-203-1112 (domestic) or +1
719-457-0820 (international). The access code for the replay is
#6010391. The telephone replay will be available
until Wednesday, November 5, 2014.
About CTI BioPharma
CTI BioPharma Corp. (NASDAQ and
MTA: CTIC) is a biopharmaceutical company focused on the
acquisition, development and commercialization of novel targeted
therapies covering a spectrum of blood-related cancers that offer a
unique benefit to patients and healthcare providers. CTI has a
commercial presence in Europe and
a late-stage development pipeline, including pacritinib, CTI's lead
product candidate that is currently being studied in a Phase 3
program for the treatment of patients with myelofibrosis. CTI is
headquartered in Seattle,
Washington, with offices in London and Milan under the name CTI Life
Sciences Limited. For additional information and to sign up for
email alerts and get RSS feeds, please visit
www.ctibiopharma.com.
Contacts:
Monique
Greer
+1 206-272-4343
mgreer@ctibiopharma.com
Ed Bell
+1 206-282-7100
ebell@ctibiopharma.com
In Europe: CTI Life Sciences Limited, Milan Branch
Laura Villa
+39 02 94751572
lvilla@cti-lifesciences.com
SOURCE CTI BioPharma Corp.